Abstract:For conventional anticancer drug delivery systems (DDSs), it is difficult to endow them with both long circulation in vivo and easy cellular endocytosis by cancer cells as well as the ability to accumulate in tumors through the enhanced permeability and retention (EPR) effect and deep intratumoral penetration. Therefore, their in vivo treatment effects are inadequate. Previous studies have shown that “dynamic protection” strategies can effectively address the difficulty of DDS entry into cancer cells as a result of modifying “stealthy” molecules such as poly(ethylene glycol) (PEG). In this work, a “Trojan horse”-like DDS was fabricated by employing the “dynamic protection” strategy. The DDS was developed using ultrasmall, degradable mesoporous silica nanoparticles (DS-MSN) that were bridged by a degradable peptide and cross-linked with 4-arm PEG-N3 through click chemistry. This resulted in DOX-DS-MSN-CD-peptide-PEG with a size of ∼300 nm, which could accumulate in the tumor, following adequate blood circulation. The peptide could be degraded by matrix metalloproteinase-2 (MMP-2), an overexpressed enzyme in tumors, leading to the release of small-sized, tumor-permeable DS-MSN-based carriers. The remaining Arg-Gly-Asp (RGD) peptide on the surface provides the carriers with a “tumor-triggered targeting” capability. DS-MSN, which includes disulfide bonds in its backbone, could be degraded due to glutathione (GSH) in cancer cells and release of the loaded doxorubicin hydrochloride (DOX). In vitro and in vivo experiments showed that DOX-DS-MSN-CD-peptide-PEG had a prolonged circulation time and tumor accumulation ability, excellent tumor penetration ability, and controlled drug release ability. It operated like a “Trojan horse”, overcoming obstacles to deliver the “Greek soldier” DOX to the interior of cancer cells, resulting in effective tumor suppression. This study offers interesting concepts for designing effective and safe drug delivery systems.

Dendrimer Nanosystems for Adaptive Tumor-Assisted Drug Delivery Via Extracellular Vesicle Hijacking.

Nanodelivery of a Self-Assembling Prodrug with Exceptionally High Drug Loading Potentiates Chemotherapy Efficacy.

A Self-Assembling Amphiphilic Peptide Dendrimer-Based Drug Delivery System for Cancer Therapy

A Ph‐responsive Nanoparticle Delivery System Containing Dihydralazine and Doxorubicin‐based Prodrug for Enhancing Antitumor Efficacy

RGD-expressed Bacterial Membrane-Derived Nanovesicles Enhance Cancer Therapy Via Multiple Tumorous Targeting

Anticancer Drug Nanomicelles Formed By Self-Assembling Amphiphilic Dendrimer To Combat Cancer Drug Resistance

Research Status of Dendrimer Micelles in Tumor Therapy for Drug Delivery

Systemically targeting monocytic myeloid-derived suppressor cells using dendrimers and their cell-level biodistribution kinetics

Extracellular vesicles-hitchhiking boosts the deep penetration of drugs to amplify anti-tumor efficacy

Systemically targeting monocytic MDSCs using dendrimers and their cell-level biodistribution kinetics

Enzyme-Triggered Transcytosis of Dendrimer-Drug Conjugate for Deep Penetration into Pancreatic Tumors

Degradable Mesoporous Silica Nanoparticle/Peptide-Based “Trojan Horse”-like Drug Delivery System for Deep Intratumoral Penetration and Cancer Therapy

A Transformable Amphiphilic and Block Polymer−Dendron Conjugate for Enhanced Tumor Penetration and Retention with Cellular Homeostasis Perturbation via Membrane Flow

Supramolecular Drug Delivery System from Macrocycle-Based Self-Assembled Amphiphiles for Effective Tumor Therapy

Dendrimers for Cancer Immunotherapy: Avidity‐based Drug Delivery Vehicles for Effective Anti‐tumor Immune Response

Magnetically and Ph Dual Responsive Dendrosomes for Tumor Accumulation Enhanced Folate-Targeted Hybrid Drug Delivery.

Engineering dendritic cell biomimetic membrane as a delivery system for tumor targeted therapy

EGF-coated Nano-Dendriplexes for Tumor-Targeted Nucleic Acid Deliveryin Vivo

Hybrid Cell Membrane-Camouflaged Nanoparticle: A Novel Multifunctional Biomimetic Drug Delivery Carrier for Cancer Therapy

Fabrication of dendrimer-releasing lipidic nanoassembly for cancer drug delivery.

Enhanced Nanodrug Delivery to Solid Tumors Based on a Tumor Vasculature-Targeted Strategy